Abstract:Previously, we have reported a new biomolecular phenomenon spanning between protein folding and binding, termed as self-binding peptides (SBPs), where a short peptide segment in monomeric protein functions as a molecular switch by dynamically binding to/unbinding from its cognate domain in the monomer (Yang et al. J. Chem. Inf. Model: 2015, 55, 329-342). Here, we attempt to raise the SBP as a new class of druggable targets to regulate the biological activity and function of proteins. A case study was performed on the proto-oncogene nonreceptor tyrosine kinase, c-Src, which contains two SBPs that bind separately to SH3 and SH2 domains of the kinase. State-of-the-art molecular dynamics (MD) simulations and post binding energetics analysis revealed that disrupting the kinase-intramolecular interactions of SH3 and SH2 domains with their cognate SBP ligands can result in totally different effects on the structural dynamics of c-Src kinase architecture; targeting the SH2 domain unlocks the autoinhibitory form of the kinase-this is very similar to the pTyr527 dephosphorylation that functionally activates the kinase, whereas targeting the SH3 domain can only release the domain from the tightly packed kinase but has a moderate effect on the kinase activity. Subsequently, based on the cognate SBP sequence we computationally designed a number of SH2-binding phosphopeptides using a motif grafting strategy. Fluorescence polarization (FP) assay observed that most of the designed phosphopeptides have higher binding affinity to SH2 domain as compared to the native SBP segment (Kd = 53 nM). Kinase assay identified a typical dose-response relationship of phosphopeptides against kinase activation, substantiating that disruption of SH2-SBP interaction can mimic c-Src dephosphorylation and activate the kinase. Two rationally designed phosphopeptides, namely EPQpYEEIEN and EPQpYEELEN, were determined as strong binders of SH2 domain (Kd = 8.3 and 15 nM, respectively) and potent activators of c-Src kinase (EC50 = 3.2 and 41 μM, respectively).

Peptide Library Screening for Determination of SH2 or Phosphotyrosine-Binding Domain Sequences

High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Phosphorylated Protein Chip Combined with Artificial Intelligence Tools for Precise Drug Screening

Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network

Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect

Phosphopeptide binding to the N-SH2 domain of tyrosine phosphatase SHP2 correlates with the unzipping of its central β-sheet

One-Step SH2 Superbinder-Based Approach for Sensitive Analysis of Tyrosine Phosphoproteome.

Reverse Binding Mode of Phosphotyrosine Peptides with SH2 Protein.

Binding-induced lipid domains: Peptide-membrane interactions with PIP2 and PS

THE STRUCTURE OF RETINAL VASCULAR SYSTEM OF THE HUMAN FETUS EYE.

Experimental measurement of the nonlinearities of electrodynamic microphones

Prediction of Binding Sites of Peptide Recognition Domains: An Application on Grb2 and SAP SH2 Domains

Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences

Targeting Self-Binding Peptides as a Novel Strategy To Regulate Protein Activity and Function: A Case Study on the Proto-oncogene Tyrosine Protein Kinase c-Src

Candesartan reduced cardiovascular mortality and morbidity in chronic heart failure with low ejection fraction.

Determination of promising inhibitors for N-SH2 domain of SHP2 tyrosine phosphatase: an in silico study

Photoaffinity-engineered Protein Scaffold for Systematically Exploring Native Phosphotyrosine Signaling Complexes in Tumor Samples

Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains

Efficient palladium-catalyzed coupling of aryl chlorides and tosylates with terminal alkynes: use of a copper cocatalyst inhibits the reaction.

Generating and validating renewable affimer protein binding reagents targeting SH2 domains